EP1146903A4 - Glypicane zur detektion und behandlung humaner karzinome - Google Patents

Glypicane zur detektion und behandlung humaner karzinome

Info

Publication number
EP1146903A4
EP1146903A4 EP99954963A EP99954963A EP1146903A4 EP 1146903 A4 EP1146903 A4 EP 1146903A4 EP 99954963 A EP99954963 A EP 99954963A EP 99954963 A EP99954963 A EP 99954963A EP 1146903 A4 EP1146903 A4 EP 1146903A4
Authority
EP
European Patent Office
Prior art keywords
glypicans
detection
treatment
human carcinoma
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99954963A
Other languages
English (en)
French (fr)
Other versions
EP1146903A1 (de
Inventor
Arthur Lander
Murray Korc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of EP1146903A1 publication Critical patent/EP1146903A1/de
Publication of EP1146903A4 publication Critical patent/EP1146903A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04011—Phosphoinositide phospholipase C (3.1.4.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
EP99954963A 1998-10-16 1999-10-15 Glypicane zur detektion und behandlung humaner karzinome Withdrawn EP1146903A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10451098P 1998-10-16 1998-10-16
US104510P 1998-10-16
US12162499P 1999-02-25 1999-02-25
US121624P 1999-02-25
PCT/US1999/024176 WO2000023109A1 (en) 1998-10-16 1999-10-15 Glypicans for the detection and treatment of human carcinoma

Publications (2)

Publication Number Publication Date
EP1146903A1 EP1146903A1 (de) 2001-10-24
EP1146903A4 true EP1146903A4 (de) 2005-02-16

Family

ID=26801634

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99954963A Withdrawn EP1146903A4 (de) 1998-10-16 1999-10-15 Glypicane zur detektion und behandlung humaner karzinome

Country Status (4)

Country Link
EP (1) EP1146903A4 (de)
AU (1) AU769125B2 (de)
CA (1) CA2346264A1 (de)
WO (1) WO2000023109A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2454135A1 (en) * 2001-07-12 2003-01-23 Exelixis, Inc. Gpcs as modifiers of the irrtk and p21 pathways and methods of use
WO2003100429A2 (en) 2002-05-23 2003-12-04 Sunnybrook And Women's College Health Sciences Centre Diagnosis of hepatocellular carcinoma
AU2002338020A1 (en) * 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CN107531755B (zh) * 2015-01-16 2022-02-25 美侬米克国际有限公司 磷脂酰肌醇蛋白聚糖表位及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69129417T2 (de) * 1991-01-15 1998-11-05 Biotie Therapies Oy Nachweis des syndecangehalts in biologischen materialien, wie geweben und körperflüssigkeiten, zur anzeige der bösartigen umwandlung von zellen

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
INKI P ET AL: "THE ROLE OF SYNDECAN-1 IN MALIGNANCIES", ANNALS OF MEDICINE, FINNISH MEDICAL SOCIETY DUODECIM, HELSINKI, FI, vol. 28, 1996, pages 63 - 67, XP002927348, ISSN: 0785-3890 *
SEBESTYEN A ET AL: "Expression of Syndecan-1 in Human B Cell Chronic Lymphocytic Leukaemia", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 33, no. 13, November 1997 (1997-11-01), pages 2273 - 2277, XP004284563, ISSN: 0959-8049 *
See also references of WO0023109A1 *

Also Published As

Publication number Publication date
AU769125B2 (en) 2004-01-15
AU1118100A (en) 2000-05-08
EP1146903A1 (de) 2001-10-24
WO2000023109A1 (en) 2000-04-27
CA2346264A1 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
GB9903841D0 (en) Diagnosis and treatment of cancer
HK1043625A1 (zh) 腎病檢測及治療
IL128850A0 (en) Medical treatment
AP9700939A0 (en) Compounds and methods for the treatment of cancer
HUP0001316A3 (en) Method for the detection and localization of malignant human tumours
IL132287A0 (en) Compositions and methods for the treatment and diagnosis of breast cancer
SI1716853T1 (sl) Zdravljenje rakov äśloveĺ kega telesa z uporabo et743
EP1015038A4 (de) Verfahren zur entdeckund, behandlung und vorbeugung von neurodegeneration
GB9805419D0 (en) Treatment of liquids
GB9811598D0 (en) Diagnosis and treatment of cancer
EP1208191A4 (de) 13 humane dickdarm- und mit dickdarmkrebs-assoziierte proteine
IL143212A0 (en) Compositions and methods for the treatment of tumor
EP1146903A4 (de) Glypicane zur detektion und behandlung humaner karzinome
IL121329A (en) Pharmaceutical composition for the treatment of cancer comprising somatostatin2 and other peptides
EP0733365A3 (de) Verwendung von Benzochinolin-3-one zur Behandlung und Vorbeugung von Prostatkarzinom
GB9812550D0 (en) Tumour therapy and imaging
GB9819999D0 (en) Treatment of cancer
GB9713189D0 (en) Appliance for the beauty treatment of parts of the human body
IL132531A0 (en) Detection and therapy of tumors
AU2351699A (en) The human calcium-sensing receptor in the detection and treatment of cancer
AU5939898A (en) Agent for the pre-symptomatic detection, prevention and treatment of breast cancer in humans
GB2343629B (en) Treatment of cellulite
GB9828564D0 (en) Materials and methods for the treatment and diagnosis of cancer
GB9716787D0 (en) Materials and methods for the diagnosis and treatment of breast cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010426

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050105

17Q First examination report despatched

Effective date: 20080124

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100504